Medicare Advantage plans have drawn the ire of lawmakers for aggressive coding. Investigations are underway. Some hope ...

Satellos Bioscience Chief Scientific Officer discusses early-stage trials of the company's Duchenne muscular dystrophy drug, ...

Repurposing existing therapies may help slow muscle weakness in patients with Duchenne muscular dystrophy, a new study ...

Phil Lambert, Ph.D., chief scientific officer of Satellos Bioscience Inc., explains the mechanism of action of the company's experimental Duchenne muscular dystrophy drug, SAT-3247, and the thinking ...

Satellos Bioscience's experimental small-molecule drug for Duchenne muscular dystrophy is showing positive results as a stand-alone treatment, but Phil Lambert, Ph.D., the company's chief scientific ...

The findings of a new study lend support for type 1 diabetes autoantibody screening in people with other autoimmune ...

Tracking the trajectory of symptoms may be an improvement over the traditional way of collecting patient-reported outcomes ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

Approximately 57% of Americans are lonely, with younger generations, Gen Z and Millennials, reporting higher levels than ...

Despite high specificity, the tests show low sensitivity for early-stage cancers, necessitating further validation through ...

The risk of major cardiac events was 50% higher in adult-onset type 1 diabetes than in population controls, and the risk of ...

Gut bacteria produce metabolites that influence drug metabolism and affect immune cell function, potentially enhancing or ...